SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
- Mechanism
- Curator reviewed · 6 references
This drug is a selective inhibitor of the COX-2 enzyme. COX-2 is expressed in the brain, in the kidney, in bone, and likely in the female reproductive system. Its expression at other sites is increased during inflammation, experimentally, in response to mitogenic stimuli. Growth factors, phorbol esters, and interleukin (IL)-1 stimulate the expression of COX-2 in fibroblasts, while endotoxin serves the same function in monocytes/macrophages.
SC-236 works also directly through suppressing the nuclear translocation of RelA/p65, a transcription factor. SC-236 directly targets proteins that facilitate the nuclear translocation of NF-κB, an inflammatory signaling pathway.
- Formula / weight
- C16H11ClF3N3O2S · 401.79 g/mol (avg)
- Code names
- SC-236
Resolves to
NSQNZEUFHPTJME-UHFFFAOYSA-NSMILESNS(=O)(=O)C1=CC=C(C=C1)N1N=C(C=C1C1=CC=C(Cl)C=C1)C(F)(F)FWhat you can answer from here — as of March 06, 2025
Which drugs share a target with SC-236, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account